BioSpace News Archive

CMAB Biopharma (Suzhou) Inc. (“CMAB”), and Laekna Therapeutics Shanghai Co., Ltd. (“Laekna Therapeutics”), today announced a strategic collaboration agreement in Suzhou BioBAY for speedup of Immune Checkpoint Inhibitor (ICI) drug candidate to the clinical trial and future commercialization.

EZbra, a fem-tech startup from Israel and the creators of the world’s first sterile and disposable post-surgical bra, today announced that they signed a Middle East Master Distributor agreement with Medica IQ in order to provide EZbra to millions of post-op women across the Emirates.

Adaptive therapy provides the ability to personalize patient treatment at the time of treatment based on patient’s anatomy and precise position -- Ethos therapy combines multi-modality images with an artificial intelligence (AI)-driven Adaptive Intelligence™ solution to enable personalized, patient-centric care -- Goshen Center for Cancer Care is the second provider in the United States and the only provider in Indiana to offer Ethos therapy -- The Ethos system’s fa

PolarityTE, Inc. (Nasdaq: PTE) , a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 and the Cantor Virtual Global Healthcare Conference on September 15, 2020. A live audio webcast of the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020

Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, originating in the United States recently opened its first office in South Korea.

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate virtually in the H.C. Wainwright Global Investment Conference on Tuesday, September 15, 2020 at 3:00 p.m. EDT. To access a live webcast of the fireside chat on the “Investor Relations” page of Entera’s website, please click here . A replay of the webcast will be a

Characterization of novel immunotherapy approach with CPI-006 and details of COVID-19 clinical trial results submitted for publication online at medRxiv.org Patients treated in first two cohorts of Phase 1 study had low pre-treatment titers of antibodies and produced robust antibody responses within 7 days of treatment Titers of IgG, IgM and neutralizing antibodies continually increased out to 28 days post-treatment BURLINGAME, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Corvus Pharma

Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for women’s cancers, today announced it has strengthened its executive team with the appointment of Shane Kovacs , M.B.A., as Chief Operating Officer/Chief Financial Officer, Kinney Horn as Chief Business O

Milestone Scientific Inc., a leading developer of computerized drug delivery instruments that provides painless and precise injections, announced that Leonard Osser, Interim Chief Executive Officer, will share insight into the company’s recent developments and upcoming milestones during an investor webinar on Monday, September 14, 2020 at 4:00 p.m. ET.

-NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship -CONTEPO first Qualified Infectious Disease Product to receive NTAP conditional approval prior to FDA approval DUBLIN, Ireland, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today